Drug Profile
Research programme: antibacterials - Pfizer/University of Auckland
Alternative Names: PD 0305970; PNU 92560Latest Information Update: 30 Mar 2005
Price :
$50
*
At a glance
- Originator Auckland Cancer Society Research Centre; Pfizer; University of Auckland
- Class
- Mechanism of Action DNA gyrase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 30 Mar 2005 Data presented at the 229th American Chemical Society National Meeting (229th-ACS-2005) have been added to the Bacterial Infections antimicrobial activity section
- 12 Nov 2004 Data presented at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2004) have been added to the Bacterial infections antimicrobial activity section ,
- 10 Feb 2004 Pfizer and the University of Auckland have renewed a research contract to extend the work of the Auckland Cancer Society into the discovery of new antibacterials